~~<i id='AA802BBFB0'><strike id='AA802BBFB0'><tt id='AA802BBFB0'><pre id='AA802BBFB0'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：hotspot 2025-10-06 17:36:43 Page View：5

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The health care issue Democrats can’t solve: hospital reform
Next article： What does generative AI mean for health care? We asked experts

Wikipedia

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Methadoneandbuprenorphine,bothFDA-approveddrugs,areconsideredthegoldstandardfortreatingopioidusediso

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

FDA approves Moderna’s RSV vaccine, its second licensed product

TheFDAhasapprovedModerna’sRSVvaccineforolderadults.ModernaTheFoodandDrugAdministrationonFridayapprov